Background: In the pediatric Multiple Sclerosis (MS) population large and controlled studies on safety and efficacy of Natalizumab have not yet been performed. In literature there have been no cases of Natalizumab-related Progressive Multifocal Leukoencephalopathy (PML) reported in paediatric population with MS.

Case Report: A 14-year-old girl presented in October 2009 diplopia, gait ataxia, vomiting and impaired mentation, preceded by asthenia, fever and left sensory loss lasting for 3 days, 1 month earlier. MRI ...

Neil's 3rd Tysabri Diary Update

Neil has tested positive for the JC virus, but is continuing his Tysabri treatments.

You can read his 3rd infusion diary update at http://www.msrc.co.uk/index.cfm/fuseact ... ageid/3224

I have has MS 10 years and reasonablly unaffected. 6 months ago I had a stressful situation at work that left me pretty badly disabled

Got steroids but to no effect. MRI says I am very active

So started Ty 2 months ago and still can hardle walk and have no energy. Should I stay on it and wait it out? If so how long has it taken others to feel even the smallest positive ...

In patients with relapsing-remitting multiple sclerosis (MS), interrupting treatment with natalizumab (Tysabri, Biogen) often leads to relapse, a new study shows.

The findings "confirm a high rate of recurrence" of magnetic resonance imaging (MRI)-defined and clinical MS disease activity starting at approximately week 12, during a 24-week interruption of natalizumab therapy, a study team notes.

"Clearly, the risk of return of disease activity during treatment interruption is notable, even with the alternative immunomodulatory therapies ...

Objective: To report on a case of progressive multifocal leukoencephalopathy (PML) after natalizumab (NTZ) treatment discontinuation.

Case report: She is a 24-years-old woman who developed a very active multiple sclerosis in 1999 when she was 12. Between 2000 and 2004 she was treated with immunomodulants (GA and interferon) and XX underwent 3 cycles of Mithoxantrone for a cumulative dose of 45 mg. Then for continuous clinical and MRI activity she started natalizumab treatment in ...

Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has extended the initial PDUFA date for its review of the supplemental Biologics License Application (sBLA) for Tysabri(R) (natalizumab).

The sBLA was submitted in December 2010 to update the Prescribing Information for Tysabri to include anti-JC virus antibody status as a factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML) in the Tysabri-treated population. The 3 month ...

Early use and long-term benefit of Tysabri (ECTRIMS and ACTRIMS)



Biogen Idec and Elan Corporation, plc today announced 28 company-supported Tysabri ® (natalizumab) presentations at the 5 th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS), held in Amsterdam, the Netherlands.

Key data indicated patients on Tysabri experienced reduced annualized relapse rates (ARR), particularly in those treated with Tysabri early in the course ...

MS patients on Tysabri: 170 PML cases, 33 deaths already (as of 4-th of October 2011).
"...as of the end of September 2011 approximately 63,500 patients were on commercial and clinical TYSABRI therapy worldwide. And that cumulatively approximately 92,200 patients have ever been treated with TYSABRI in the post-marketing setting," said Biogen Idec.

Patients with multiple sclerosis (MS) who took the new generation anti-inflammatory medication natalizumab for two years had a lower risk of experiencing relapses and progression of their disability, according to a new study.

MS experts say the research is useful because it confirms results from earlier trials.

Natalizumab (NTZ), which is also known by its brand name Tysabri, is recommended for use in the NHS for patients with severe relapsing-remitting MS which is deteriorating ...

According to information released by Biogen Idec, as of September 1, 2011 there have been 159 confirmed cases of progressive multifocal leukoencephalopathy (PML, a viral infection of the brain that usually leads to death or severe disability) among people who have used Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) after it became available for prescription in July 2006.

Eighteen percent of those who have developed PML have died (29 out of 159). The degree ...